ATR 1072
PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) Syndrome
Pre-clinicalIND filing planned for H2 2026
Key Facts
Indication
PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) Syndrome
Phase
Pre-clinical
Status
IND filing planned for H2 2026
Company
About Atrium Therapeutics
Atrium Therapeutics is a private biotech company focused on transforming the standard of care for cardiac diseases by addressing their underlying genetic causes. The company launched with approximately $270 million in funding and leverages a proprietary RNA delivery platform, derived from Avidity Biosciences' AOC technology, to enable targeted oligonucleotide therapy for the heart. Its initial pipeline targets rare, life-threatening cardiomyopathies with high unmet need, positioning it as a leader in the emerging field of precision cardiology.
View full company profile